Can biosimilars help achieve the goals of US health care reform? - Wikidata - awgldk - TriplyDB

Can biosimilars help achieve the goals of US health care reform?

Can biosimilars help achieve the goals of US health care reform?

http://www.wikidata.org/entity/Q38670950

about

A bibliometric analysis of the global research on biosimilars.The role of biosimilars in value-based oncology care

P2860

Q55239713-8124188F-5338-4377-B56B-AC8869F613E3 Q58605622-EC3BB71F-9467-4E78-8441-048A24073903

P2860

Can biosimilars help achieve the goals of US health care reform?

http://www.wikidata.org/entity/Q38670950

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Can biosimilars help achieve the goals of US health care reform?

@en

type

label

Can biosimilars help achieve the goals of US health care reform?

@en

prefLabel

Can biosimilars help achieve the goals of US health care reform?

@en

P1433

Q38670950-7D1A2E48-4772-4680-ABE3-A42AB15AE6C4

P1476

Q38670950-D0D337CA-30CF-4865-B28B-7FF0F348EC12

P2093

Q38670950-28F5EE6B-B428-44B0-AF31-61B40E38E4B2

Q38670950-2ACB119E-6D84-45A8-82B0-C8F65F787AB7

Q38670950-95E0DAC8-CFD7-4504-A454-82A3D164614C

Q38670950-CDA21818-BB78-4B56-B12F-94ECDAECE6B6

P2860

Q38670950-27EBE33B-F9D1-4071-B787-D41AA7C419E2

Q38670950-2AB99EEA-2699-493E-9DF7-387EA6BBA884

Q38670950-2F5B0B45-B2A9-4370-AE40-835AF918C6A5

Q38670950-30DFA8EB-B1C3-4633-8385-A6F94EC0B59A

Q38670950-32C67022-F807-47CB-8F03-9790B99ECDCA

Q38670950-40CA6B9B-7E09-4D4F-93E6-872BED6EF7F9

Q38670950-5D301A18-297C-48CE-96FB-932FDA3692A4

Q38670950-5FC97117-77CB-42C5-8CEE-FF95D2211AA5

Q38670950-6CB585C2-62CB-49A2-8A3C-83C72A88C51E

Q38670950-713C56C8-1970-435A-B0C3-7F87246B3C5B

P304

Q38670950-4EADE657-61B1-4215-8701-36B39052E210

P31

Q38670950-A80D8A93-1EA1-4005-B101-B10DDD1C052B

P356

Q38670950-67221736-CF67-4B3E-9BA0-8C861A878D0C

P407

Q38670950-00A714AA-D0C2-4886-B26C-D61401A92BFE

P478

Q38670950-D72DC39B-BD42-476C-88AC-59C3FC182333

P577

Q38670950-855203D5-D9B4-47F9-97BB-0BEC1DBDB513

P698

Q38670950-D0B4F477-F652-4B04-B310-7D9AC407D39C

P921

Q38670950-5B0E6D73-6FCA-4BA6-86B0-F1AFD074FC39

P932

Q38670950-501CB9C1-B4C5-48B9-A400-ED2229798A86

P356

P1433

Cancer Management and Research

P1476

Can biosimilars help achieve the goals of US health care reform?

@en

P2093

Gilberto de Lima Lopes

http://www.w3.org/2001/XMLSchema#string

Ira Jacobs

http://www.w3.org/2001/XMLSchema#string

Ralph Boccia

http://www.w3.org/2001/XMLSchema#string

Robert Popovian

http://www.w3.org/2001/XMLSchema#string

P2860

United States Health Care Reform: Progress to Date and Next Steps

The changing landscape of biosimilars in rheumatology

What do people really think of generic medicines? A systematic review and critical appraisal of literature on stakeholder perceptions of generic drugs

Are biosimilars the next tool to guarantee cost-containment for pharmaceutical expenditures?

The economics of biosimilars.

Are ACOs the Answer to High-Value Healthcare?

A review of approaches for the management of specialty pharmaceuticals in the United States

Interventions promoting the acceptance and uptake of generic medicines: a narrative review of the literature.

Potential cost savings from chemotherapy-induced febrile neutropenia with biosimilar filgrastim and expanded access to targeted antineoplastic treatment across the European Union G5 countries: a simulation study.

Emerging patient safety issues under health care reform: follow-on biologics and immunogenicity.

P304

197-205

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/CMAR.S133442

http://www.w3.org/2001/XMLSchema#string

P407

P478

9

http://www.w3.org/2001/XMLSchema#string

P577

2017-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28615973

http://www.w3.org/2001/XMLSchema#string

P921

P932

5459961

http://www.w3.org/2001/XMLSchema#string